J&J reports two-year psoriasis drug data for high-impact sites
Johnson & Johnson (NYSE:JNJ) recently unveiled the long-term results from its Phase 3 ICONIC-TOTAL study, which examined the effectiveness of ICOTYDE (icotrokinra) in treating plaque psoriasis that affects high-impact areas of the body. The study involved adults and adolescents battling moderate to severe psoriasis in sensitive areas such as the scalp, genitals, hands, and feet.
Presenting at the European Academy of Dermatology and Venereology Congress 2026, J&J shared findings that showcased the drug's impressive efficacy over a two-year period.
By the 112-week mark, an impressive 60% of patients dealing with scalp psoriasis had achieved complete skin clearance, as determined by scalp-specific Investigator’s Global Assessment scores. Genital psoriasis saw an even higher success rate, with 89% of patients attaining complete clear skin. For hand and foot psoriasis, 63% of patients experienced complete clearance by the end of the two-year study.
Overall, patients treated with ICOTYDE saw significant improvements in skin clarity, with rates climbing from 57% at Week 16 to 67% at Week 24 and a further increase to 70% at the 112-week point.
Nail psoriasis also showed positive results, with patients experiencing a gradual improvement in their Modified Nail Psoriasis Severity Index. The mean percentage improvement grew from 33% at Week 16 to 62% at Week 52 and reached 71% at the final point of the study, at Week 112. J&J emphasized that the safety profile of ICOTYDE remained unchanged throughout the study, with no new safety concerns identified.
The drug, which is already approved in the U.S. for treating moderate-to-severe plaque psoriasis in adults and children aged 12 and older, is also approved in Europe, Japan, and China for treating adults and adolescents with psoriasis.
ICOTYDE, a joint discovery between Protagonist Therapeutics and Johnson & Johnson, is administered orally once daily. The company is now poised to bring this innovative treatment option to patients worldwide, offering hope for those struggling with the most visible and disabling forms of psoriasis.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
